Bio-Rad Laboratories (BIO) investor relations material

Executive team and strategic focus

• New executive team with operational backgrounds is focused on evolving the business in challenging markets.

• Emphasis on understanding the portfolio, identifying areas with a right to win, and evolving or exiting where necessary.

• M&A is used to supplement growth and margin expansion, with a shift toward acquiring established, revenue-generating companies.

• Recent restructurings are part of a multi-year, methodical journey to align cost structure and strategy.

• CEO is actively involved in driving change and supporting the multi-year transformation.

Technology leadership and market positioning

• Droplet Digital PCR technology is a core differentiator, with a large assay library and extensive technical validation.

• The Stilla acquisition expanded the digital PCR portfolio, enabling coverage from entry-level to high-throughput instruments.

• Digital PCR is positioned for growth in both tools and diagnostics, supported by partnerships and technical leadership.

• NGS and PCR are seen as complementary technologies, with digital PCR excelling in rare event detection and quantitation.

• Focus remains on leveraging technology and portfolio breadth to maintain and expand market leadership.

End market dynamics and growth challenges

• Later-stage and commercial-stage biotech customers are showing improvement, while early-stage biotech remains weak.

• Academic and government markets are soft but show some positive signs, with funding sentiment and grant structures evolving.

• Europe faces deteriorating funding as governments prioritize other sectors, while APAC (excluding China) is positive.

• China remains a small but complex market, with challenges in both tools and diagnostics due to local policies and reimbursement changes.

• Growth depends on portfolio differentiation and the ability to pivot toward areas with stronger funding and demand.